Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0E3ZG)

Drug Name
REGN3048 Drug Info
Indication
Disease Entry ICD 11 Status REF
Coronavirus infection 1D92 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM0E3ZG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting COVID-19 spike glycoprotein (S)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Toremifene DMQYUWG Breast cancer 2C60-2C65 Approved [3]
Nafamostat DMU1XOD Pancreatitis DC31-DC34 Approved [4]
GSK4182136 DMYH2FI Coronavirus Disease 2019 (COVID-19) 1D6Y Approved in EU [5]
LY-CoV555 DM6LVCQ Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [6]
REGN-COV2 DM0KBML Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [7]
JS016 DMGEZVF Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1/2 [8]
REGN3051 DM7LIV2 Coronavirus infection 1D92 Phase 1 [2]
GSK4182137 DMJJW2Y Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1 [5]
MERS-4 DMS6KT8 Coronavirus infection 1D92 Preclinical [9]
MERS-27 DMVGIB4 Coronavirus infection 1D92 Preclinical [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
COVID-19 spike glycoprotein (S) TTZ3COY SPIKE_SARS2 Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03301090) A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051. U.S. National Institutes of Health.
2 Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71.
3 Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020.
4 Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline
6 Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. N Engl J Med. 2021 Jan 14;384(2):189.
7 REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251.
8 Clinical pipeline report, company report or official report of Lilly.
9 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.